Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
You may also be interested in...
Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo
Yervoy/Opdivo combo proves significant survival benefit over Yervoy alone in Phase III frontline melanoma study, but is on par with Opdivo alone in patients with higher PD-L1 expression.
What's Next For Bristol's Opdivo/Yervoy Combination
Updated data from CheckMate 012 of Yervoy/Opdivo in first-line lung cancer bode well for the Phase III CheckMate 227 study, plus other indications, Bristol says.
AstraZeneca’s Durvalumab/Tremelimumab Combo Holds Its Own In NSCLC
Phase Ib results for PD-L1/CTLA-4 combination look competitive, but editorial questions whether the company has moved too fast with development in response to intense market pressure.